Xavier Roblin

19PUBLICATIONS
41CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Nutritional epidemiologyRadiology and organ imagingVeterinary virologyGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Oct 13, 2025
Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis.

Marc Ferrante, Laurent Peyrin-Biroulet, Perttu Arkkila

|Sep 29, 2025
Gut Microbiota Are More Strongly Associated With Impairments in Health-Related Quality of Life Than Disease Activity in Inflammatory Bowel Disease.

Robert D Little, Thisun C Jayawardana, Fan Zhang

|Feb 13, 2023
Use of imaging modalities for decision-making in inflammatory bowel disease.

Stéphane Nancey, Mathurin Fumery, Mathias Faure

|Oct 27, 2022
Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease-Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics.

Robert D Little, Mark G Ward, Emily Wright

|Sep 20, 2021
SARS-CoV-2 vaccination in patients with inflammatory bowel disease.

Ralley E Prentice, Clarissa Rentsch, Aysha H Al-Ani

|Sep 27, 2020
Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure.

Emma Flanagan, Peter R Gibson, Emily K Wright

Pageof 4

Frequent Collaborators

5 joint publications

Sparrow Mp

2 joint publications

Robert D Little

2 joint publications

R W Leong

2 joint publications

David J Gibson